Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415687 | 1.00 | PIN1 (0.37) | PIN1GPR52VNN1HAO1RIPK1 | |
| SCHEMBL29415696 | 0.85 | PGR (0.39) | GPR52RIPK1 | |
| SCHEMBL19207821 | 0.85 | PGR (0.39) | GPR52RIPK1 | |
| SCHEMBL29415679 | 0.80 | BRS3 (0.47) | PIN1VNN1 | |
| SCHEMBL19207971 | 0.80 | BRS3 (0.47) | PIN1VNN1 | |
| SCHEMBL15964735 | 0.75 | HCAR2 (0.53) | — | |
| SCHEMBL15964637 | 0.74 | BRS3 (0.41) | — | |
| SCHEMBL25941184 | 0.70 | RXRA (0.48) | VNN1 | |
| SCHEMBL23927445 | 0.70 | NTRK1 (0.43) | — | |
| SCHEMBL30091689 | 0.69 | RPS6KB1 (0.38) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | PIN1 2472/4885GPR52 4052/4885VNN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.